Entera Bio Beats Q2 EPS Estimates
Entera Bio ( NASDAQ:ENTX ) , a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most notable news was a better-than-expected GAAP earnings per share of $0.06, compared to Wall ...
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates - Entera Bio ( NASDAQ:ENTX )
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density ( BMD ) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
JERUSALEM, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.
OPKO Health ( OPK ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025, at 4:30 p.m. ETNeed a quote from one of our analysts? Email [email protected] reading ...
Opko Health ( OPK ) Q2 Revenue Falls 14%
Opko Health ( NASDAQ:OPK ) , a diversified healthcare company operating in diagnostics and pharmaceuticals, released its second quarter 2025 results on July 31, 2025. The company reported a significant revenue miss, with total GAAP revenue at $156.8 million, compared to analyst expectations of ...
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
OPKO Health ( OPK ) Reports Q2 Loss, Lags Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of -58.33% and -5.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
JERUSALEM, July 28, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S.
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis - Entera Bio ( NASDAQ:ENTX )
JERUSALEM, July 28, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ENTX, a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S.
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
MIAMI, June 25, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( Nasdaq: OPK ) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing ...
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - OPKO Health ( NASDAQ:OPK )
Will provide expertise across ModeX's portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX's promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets ...
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
JERUSALEM, May 09, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025.
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
OPKO Health ( OPK ) Reports Q1 Loss, Lags Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of -66.67% and 8.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - OPKO Health ( NASDAQ:OPK ) , Philip Morris Intl ( NYSE:PM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Eric Joseph initiated coverage on OPKO Health, Inc. OPK with a Neutral ...
Down -24.31% in 4 Weeks, Here's Why OPKO Health ( OPK ) Looks Ripe for a Turnaround
OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( NASDAQ: OPK ) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million.
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
MIAMI, April 04, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( NASDAQ: OPK ) today announced that its Board of Directors has authorized an increase of $100 million to the Company's existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million.
LH Stock to Gain From Launch of HPV and STI Self-Collection Options
Labcorp launches self-collection options for HPV and STI testing in its PSCs.
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( NASDAQ: OPK ) and Entera Bio Ltd. ( NASDAQ: ENTX ) , a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the ...
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands
The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.
Opko Health ( OPK ) Q4 2024 Earnings Call Transcript
OPK earnings call for the period ending December 31, 2024.
OPKO Health ( OPK ) Beats Q4 Earnings and Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of 109.09% and 18.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation ( PRCT ) Reports Q4 Loss, Tops Revenue Estimates
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 0% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to OPKO Health ( OPK ) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of OPKO Health (OPK) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Entera Bio to Participate in Upcoming Events
JERUSALEM, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , ( "Entera" or the "Company" ) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences.
Human Growth Hormone Market Size is Expected to Reach USD 18.75 Billion by 2033, Growing at a CAGR of 11.90%: Straits Research
New York, United States, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Somatotropin, or human growth hormone, is a peptide hormone made by the pituitary gland that controls cell growth, reproduction, metabolism, and regeneration. These processes are all necessary for general human growth.
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 27, 2025 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , ( "Entera" or the "Company" ) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 35th ...
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. ( Nasdaq: OPK ) announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco.
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference - OPKO Health ( NASDAQ:OPK )
MIAMI, Jan. 09, 2025 ( GLOBE NEWSWIRE ) -- OPKO Health, Inc. OPK announced today that management will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 at Westin St. Francis hotel in San Francisco.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains
OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.
Applied Therapeutics Appoints John H. Johnson as Executive Chairman - Applied Therapeutics ( NASDAQ:APLT ) , Reviva Pharmaceuticals ( NASDAQ:RVPH )
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer NEW YORK, Dec. 20, 2024 ( GLOBE NEWSWIRE ) -- Applied Therapeutics, Inc. APLT, a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the ...
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Cautious investors have long known that healthcare spending rises steadily regardless of the direction of the overall economy. It's considered a defensive sector, but it still contains stocks that can shoot through the roof, given the right conditions.This year, the stars aligned for GeneDx ...
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Entera Bio Ltd. ( NASDAQ: ENTX ) , ( "Entera" or the "Company" ) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
Opko Health ( OPK ) Q3 2024 Earnings Call Transcript
OPK earnings call for the period ending September 30, 2024.
OPKO Health ( OPK ) Q3 Earnings Surpass Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of 130% and 4.26%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey ...
Waters ( WAT ) Beats Q3 Earnings and Revenue Estimates
Waters (WAT) delivered earnings and revenue surprises of 9.33% and 3.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
WESTON, Mass., Oct. 07, 2024 ( GLOBE NEWSWIRE ) -- ModeX Therapeutics Inc., an OPKO Health, Inc. ( NASDAQ: OPK ) company, announces it has been awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority ( BARDA ) , part of ...
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program - OPKO Health ( NASDAQ:OPK )
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding ...
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
